Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
HIV-1 has evolved many ways to evade protective host immune responses, thus creating a number of problems for HIV vaccine developers. In particular, durable, broadly specific neutralizing antibodies to HIV-1 have proved difficult to induce with current HIV-1 vaccine candidates. The recent observation that some broadly neutralizing anti-HIV-1 envelope monoclonal antibodies have polyspecific reactivities to host antigens have raised the hypothesis that one reason antibodies against some of the conserved HIV-1 envelope trimer neutralizing epitopes are not routinely made may be down-regulation of some specificities of anti-HIV-1 antibody producing B cells by host B cell tolerance mechanisms.
Haynes
Barton F
BF
Duke Human Vaccine Institute, Duke University School of Medicine, Durham NC 27710, USA. hayne002@mc.duke.edu
Moody
M Anthony
MA
Verkoczy
Laurent
L
Kelsoe
Garnett
G
Alam
S Munir
SM
D016915:AIDS Vaccines / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity; D001402:B-Lymphocytes / Q000276:immunology; D015483:HIV Antibodies / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests / Q000379:methods
D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D015488:HIV Antigens